Amylyx Pharmaceuticals Highlights Avexitide LUCIDITY Phase 3 Enrollment, Q3 Data Timing at ...

CEO Justin Klee discussed the company’s lead endocrine program, avexitide, and provided updates on its pivotal LUCIDITY trial ...

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim ...